Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5903469 | 0.93 | POLB (0.66) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL4189768 | 0.88 | CYP1A2 (0.58) | KMT2AALDH1A1MEN1POLBMAPT | |
| SCHEMBL13872559 | 0.87 | KMT2A (0.50) | KMT2AALDH1A1MEN1POLBLMNA | |
| SCHEMBL4196076 | 0.86 | ALDH1A1 (0.53) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL2378489 | 0.84 | PKM (0.66) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL27337231 | 0.84 | ABL1 (0.58) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL15546620 | 0.80 | PKM (0.66) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL28024114 | 0.78 | POLB (0.73) | KMT2AALDH1A1MEN1POLBMTOR | |
| SCHEMBL5813426 | 0.78 | ALDH1A1 (0.87) | KMT2AALDH1A1MEN1POLBPKM | |
| SCHEMBL22995880 | 0.78 | ALDH1A1 (0.55) | KMT2AALDH1A1MEN1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060016023-A1 | Novel m-phenylenediamine derivatives as coupler components for the colouring of keratin fibres | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-01-26 | — | — | US | claimed |
| EP-1575538-A1 | NOVEL M- PHENYLENDIAMINE DERIVATIVES AS COUPLER COMPONENTS FOR THE COLOURING OF KERATIN FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058201-A1 | NOVEL M- PHENYLENDIAMINE DERIVATIVES AS COUPLER COMPONENTS FOR THE COLOURING OF KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-07-15 | — | — | WO | claimed |
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-7135047-B2 | M-phenylenediamine derivatives as coupler components for the coloring of keratinic fibers | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-11-14 | — | — | US | disclosed |
| US-20060016023-A1 | Novel m-phenylenediamine derivatives as coupler components for the colouring of keratin fibres | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (HENKEL KGAA) (DE) | 2006-01-26 | — | — | US | disclosed |
| EP-1575538-A1 | NOVEL M- PHENYLENDIAMINE DERIVATIVES AS COUPLER COMPONENTS FOR THE COLOURING OF KERATIN FIBRES | Henkel Kommanditgesellschaft auf Aktien (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058201-A1 | NOVEL M- PHENYLENDIAMINE DERIVATIVES AS COUPLER COMPONENTS FOR THE COLOURING OF KERATIN FIBRES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | KMT2A 2799/4885ALDH1A1 2102/4885MEN1 2881/4885 |
| US-20060016023-A1 | Novel m-phenylenediamine derivatives as coupler components for the colouring of keratin fibres | KRT18, VIM, TPM4 | KMT2A 623/4885ALDH1A1 2258/4885MEN1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.